Dexcom Inc banner

Dexcom Inc
NASDAQ:DXCM

Watchlist Manager
Dexcom Inc Logo
Dexcom Inc
NASDAQ:DXCM
Watchlist
Price: 65.68 USD -0.18% Market Closed
Market Cap: $25.3B

Dexcom Inc
Narrow Economic Moat

No Moat
Narrow
Wide
What is Economic Moat?

Narrow economic moat driven primarily by proprietary sensor IP and data-driven ecosystem, reinforced by switching costs and concentrated market dynamics.

Dexcom Inc
Competitive Advantages

Network Effects

Cloud/mobile data sharing, caregiver/follower features and integrations with pump/health platforms increase product value as more patients and clinical partners adopt the Dexcom ecosystem.

High Switching Costs

Longitudinal patient glucose datasets, clinical workflows and integrations with insulin delivery and clinician systems create high clinical and behavioral friction for users to switch vendors.

Intangible Assets

Extensive proprietary sensor and algorithm IP and regulatory-cleared product generations (e.g., G7 15‑day) that protect core sensing technology and support product differentiation and commercial launches.

Efficient Scale

CGM distribution is highly concentrated with large fixed regulatory and manufacturing barriers, favoring incumbent scale for R&D, production and reimbursement relationships over smaller entrants.

View Wide Economic Moat Stocks

Wide Economic Moat Companies

Company Last Price Price Change Market Cap Economic Moat
NVIDIA Corp
NVDA
$183.91
+0.9%
$4.5T Wide
Apple Inc
AAPL
$260.49
+2.1%
$3.8T Wide
Alphabet Inc
GOOGL
$318.49
-0.2%
$3.9T Wide
Microsoft Corp
MSFT
$373.07
+1%
$2.8T Wide
Amazon.com Inc
AMZN
$233.65
+1.7%
$2.5T Wide
Taiwan Semiconductor Manufacturing Co Ltd
2330
NT$1 990
+2.6%
$1.6T Wide
Meta Platforms Inc
META
$628.39
+0.1%
$1.6T Wide
Broadcom Inc
AVGO
$354.91
-2%
$1.7T Wide
Walmart Inc
WMT
$129.13
+0.6%
$1T Wide
Eli Lilly and Co
LLY
$955.19
-1.3%
$903B Wide
Load More
Company Last Price Price Change Market Cap Economic Moat
AstraZeneca PLC
AZN
GBX15 306
-0.1%
$320.3B Wide
Kweichow Moutai Co Ltd
600519
¥1 455.39
+1.7%
$264.8B Wide
Novo Nordisk A/S
NOVO B
kr242
-1.9%
$169.5B Wide
Zhongji Innolight Co Ltd
300308
¥739.14
+2.6%
$119.3B Wide
Advantest Corp
6857
¥24 990
+7.3%
$118.3B Wide
Eoptolink Technology Inc Ltd
300502
¥519.7
+2.7%
$75B Wide
Disco Corp
6146
¥66 890
+5.3%
$46.9B Wide
Gold Fields Ltd
GFI
Zac80 076
-1.5%
$44.9B Wide
Suzhou TFC Optical Communication Co Ltd
300394
¥361.96
-4.1%
$40.9B Wide
GE Healthcare Technologies Inc
GEHC
$72.91
+0%
$33.2B Wide
Load More

Dexcom Inc
Glance View

Dexcom Inc. emerged as a pioneering force in the realm of continuous glucose monitoring (CGM), redefining the landscape of diabetes management. Founded in 1999, this San Diego-based company disrupted traditional blood glucose monitoring with its innovative technology, allowing individuals to track glucose levels in real-time without frequent finger-pricking. The company’s CGM systems, such as the G6 model, utilize a small sensor inserted beneath the skin that transmits data to a wearable device or smartphone, allowing patients and healthcare providers a comprehensive view of glucose trends. This approach empowers users with critical information for better diabetes management, reducing the likelihood of complications resulting from high or low blood sugar. Dexcom’s revenue generation revolves around the sales of its CGM systems, sensors, and related software services. By selling the initial monitoring devices and disposable sensors that typically need to be replaced every ten days, the company ensures a steady, recurring revenue stream. Furthermore, its integration with healthcare providers and insurers broadens its reach, tapping into a vast network of patients worldwide. Dexcom also collaborates with tech giants to enhance interoperability and data analytics, thereby embedding its solutions in broader digital health ecosystems. As diabetes continues to be a growing global concern, Dexcom’s strategic focus on innovation and strategic partnerships positions it as a leader in the CGM market.

DXCM Intrinsic Value
LOCKED
Unlock
The Power of Economic Moat

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

The Power of
Economic Moat
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett